Ultromics, the Oxford-based AI healthtech company, has raised $55 million in Series C funding to accelerate deployment of its FDA-cleared platform for early heart failure detection.
The round was co-led by Legal & General (L&G), Allegis Capital, and Lightrock, with participation from GV, Oxford Science Enterprises, Blue Venture Fund, UChicago Medicine (UCM Ventures), UPMC Enterprises, and the University of Oxford.
A diagnostic breakthrough for one of medicine’s biggest blind spots
Ultromics’ core product, EchoGo®, is an AI-powered platform trained on 430,000+ echocardiograms. It detects elusive cardiac conditions like HFpEF (heart failure with preserved ejection fraction) and cardiac amyloidosis, which are missed in up to 64% of cases. The tool integrates with existing clinical workflows and is now fully reimbursable under Medicare for both inpatient and outpatient use in the U.S.
Advertisement
AI that reads the most common heart scan in the world
Unlike traditional systems that require expensive hardware, EchoGo® analyzes standard ultrasound scans to flag hidden disease signals. It generates real-time probability scores and integrates seamlessly into existing cardiology workflows, with no disruption. The platform is now deployed in top institutions including Mayo Clinic, Northwestern, and University Hospitals Cleveland.
Scaling in the U.S. to meet a $70B cost crisis
Heart failure drives over $30B annually in U.S. healthcare costs, projected to hit $70B by 2030. Ultromics is expanding rapidly in high-prevalence regions such as the Midwest, helping health systems reduce unnecessary testing, triage at-risk patients, and initiate treatment earlier.
Platform roadmap: new diagnostics and deeper partnerships
With the Series C, Ultromics plans to:
- Expand across more U.S. hospitals and echo labs
- Develop new diagnostic tools for additional cardiac conditions
- Scale partnerships with large health systems and clinical networks
- Invest in further AI development and global regulatory pathways
Backed by healthtech insiders and strategic capital
“This is a critical moment for cardiovascular care,” said CEO and founder Dr. Ross Upton. “We’re helping hospitals use the data they already have to detect life-threatening heart conditions earlier — before it’s too late.”
Investors view Ultromics as a platform play for cardiology. “They’ve built one of the first commercially available AI diagnostic tools in cardiovascular medicine,” said Alastair Stewart, Head of VC at L&G. “This round reflects the scale of the opportunity.”
